IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
Rhea-AI Summary
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Launch of a new precision oncology assay for breast cancer treatment using RPPA technology
- Successful clinical case study demonstrating complete response to therapy guided by RPPA-based analysis
- Only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors
- Potential to revolutionize targeted cancer therapies and improve patient outcomes
Negative
- None.
Insights
This groundbreaking case study demonstrates the potential of Reverse Phase Protein Array (RPPA) technology in precision oncology. The ability to detect HER2 activation missed by conventional methods is a significant advancement. It highlights the limitations of current IHC and NGS testing, which may overlook important protein activations. This technology could revolutionize treatment decisions, especially for triple-negative breast cancer patients who typically have targeted therapy options.
The complete response achieved in this case is particularly noteworthy. It suggests that RPPA could identify more patients who might benefit from HER2-targeted therapies, potentially expanding the use of drugs like trastuzumab deruxtecan. However, larger studies are needed to confirm these findings and establish the predictive value of RPPA in various cancer types.
The launch of Ignite Proteomics and its novel RPPA assay positions IMAC Holdings (NASDAQ: BACK) at the forefront of the precision oncology market. This market is projected to reach
However, investors should consider:
- The cost and scalability of RPPA technology
- Potential competition from established diagnostic companies
- The need for further clinical validation and regulatory approvals
The introduction of RPPA technology by Ignite Proteomics could significantly impact cancer treatment protocols and healthcare policies. If further validated, this approach might necessitate updates to clinical guidelines for breast cancer diagnosis and treatment. The potential to identify more patients who could benefit from targeted therapies could lead to:
- Improved patient outcomes
- More cost-effective treatment strategies
- Reduced use of ineffective therapies
However, the healthcare system will need to address challenges such as:
- Integrating RPPA testing into standard diagnostic workflows
- Ensuring equitable access to this advanced technology
- Developing appropriate reimbursement models
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC (“Ignite Proteomics”). This launch follows IMAC Holdings’ strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study “Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer”, demonstrating the power of RPPA technology in precision oncology published in npj Precision Oncology, an international, peer-reviewed journal focused on precision oncology.
Revolutionizing Cancer Care with Precision Oncology
Ignite Proteomics introduces the only commercialy available and clinically validated assay that can measure both the expression and activated protein drug target levels in breast tumors, a superior way to measure the potential effectiveness of targeted cancer therapies. The clinical utility of the Ignite proteomic assay is highlighted by this recent case study involving a 57-year-old woman with metastatic triple-negative breast cancer (TNBC) who exhibited an exceptional response to treatment guided by Ignite’s RPPA-based analysis.
Case Study Highlights: A Breakthrough in Precision Medicine
Despite previous extensive treatments including chemotherapy and targeted therapies, the patient experienced disease progression across multiple sites (brain, mediastinal lymph nodes, lungs, chest wall, liver, and skin). A clinical trial at the Inova Schar Cancer Institute (ISCI) allowed for a comparative analysis using both current next-generation sequencing (NGS) assays and Ignite’s novel assay on the same biopsy. After Ignite Proteomics RPPA assay identifed the expression and activation of an important protein called HER2, which was missed by both the NGS analysis and current approaches to measure HER2 the patient was treated with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) , which relies on HER2 expression and activation to work. After 9 cycles no measurable disease was observed, representing a complete response to therapy.
“The RPPA technology and our novel proteomics assay represent a transformative advancement in the management of breast cancer, providing critical insights that enable us to tailor treatments with greater precision and effectiveness,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics. “The remarkable response observed in this case study underscores the role our assay can play in significantly impacting patient outcomes.”
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is dedicated to advancing healthcare through innovative solutions that improve patient outcomes. With a focus on strategic acquisitions and pioneering technologies, IMAC Holdings is at the forefront of precision medicine.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay for breast cancer, Ignite Proteomics is setting new benchmarks in protein-based testing and personalized oncology care.
For additional information, please contact:
Investors@imacholdings.com
